GlassScriptPhysician profile
Bertha A Gonzalez
NPI 1932295680
$6,807.35
in general payments reported to CMS, 2019-2025
34 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $1,082 · 2021: $1,603 · 2022: $938 · 2023: $685 · 2024: $856 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,276.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $909.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $546.72 | 2021-2025 | |
| Abbott Laboratories | $528.62 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $464.78 | 2020-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $360.16 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.16 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $259.10 | 2021-2025 | |
| Almatica Pharma LLC | $217.28 | 2021-2024 | Loreev Xr, Teriparatide |
| Teva Pharmaceuticals USA, INC. | $200.86 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $199.07 | 2023-2025 | Gemtesa |
| Kvk-Tech, INC. | $182.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $173.26 | 2019-2022 | |
| Allergan, INC. | $120.60 | 2020 | |
| Astellas Pharma US INC | $119.35 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $116.29 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $91.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $84.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $83.68 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $71.21 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $64.03 | 2021 | |
| Dexcom, INC. | $51.60 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $44.04 | 2025 | Gvoke Hypopen |
| Biogen, INC. | $39.35 | 2020 | |
| Exact Sciences Corporation | $33.86 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.78 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $29.46 | 2023 | Vivjoa |
| Hologic Sales and Service, LLC | $28.71 | 2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $23.69 | 2022 | |
| Optinose US, INC. | $22.11 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.96 | 2024 | Voquezna |
| Pfizer INC. | $20.35 | 2020 | |
| Glaxosmithkline, LLC. | $20.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bertha Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.